Aanjaay Industries appoints Twinkle Agarwal as secretarial auditor

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Aanjaay Industries appoints Twinkle Agarwal as secretarial auditor
  • Tenure covers financial years 2026-27 to 2027-31
  • Appointment approved by board on September 2, 2026
  • Move ensures compliance with Companies Act and SEBI LODR
powered bylight_fuzz_icon
49906391

*this image is generated using AI for illustrative purposes only.

Aanjaay Industries Limited has appointed Twinkle Agarwal as its secretarial auditor. The company, formerly known as Kabra Drugs Limited, confirmed the decision following a board meeting held on September 2, 2026.

The appointment covers the financial years from 2026-27 to 2027-31. The move is aimed at ensuring compliance with the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

Mrs. Agarwal is a Practicing Company Secretary with Membership No. 52868 and Certificate of Practice No. 25605. She will conduct the secretarial audit for the specified period.

The company disclosed the appointment pursuant to Regulation 30 of the SEBI LODR Regulations, read with Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated January 30, 2026.

Auditor Profile

Twinkle Agarwal is a member of the Institute of Company Secretaries of India and a commerce graduate from St. Xavier's College. Her expertise includes corporate laws, securities laws, corporate governance, and ROC compliances.

She has previously assisted various listed and unlisted companies in adhering to corporate laws and has been involved in secretarial audits and forensic audits.

Particulars Details
Auditor Name Twinkle Agarwal
Designation Secretarial Auditor
Tenure Financial Year 2026-27 to 2027-31
Appointment Date September 2, 2026
Regulatory Basis Companies Act, 2013; SEBI LODR Regulations, 2015

Historical Stock Returns for Kabra Drugs

1 Day5 Days1 Month6 Months1 Year5 Years
+0.76%-6.60%-17.60%-35.12%+8.49%0.0%

How might the extended five-year tenure of the secretarial auditor impact Aanjaay Industries' long-term corporate governance stability?

What specific compliance challenges or regulatory risks is Aanjaay Industries likely addressing by appointing an auditor with forensic audit expertise?

Could this appointment signal upcoming strategic changes or restructuring within Aanjaay Industries that require enhanced legal and regulatory oversight?

Aanjaay Industries schedules board meeting for September 2, 2026

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Aanjaay Industries schedules board meeting for September 2, 2026
  • Agenda includes approving FY26 Director’s Report and Corporate Governance Report
  • Board to fix AGM date, time, and venue
  • Re-appointment of director Kuniamuthur Nanjappan Anand recommended
  • Appointment of internal and secretarial auditors for upcoming years
powered bylight_fuzz_icon
49366804

*this image is generated using AI for illustrative purposes only.

Aanjaay Industries Limited (formerly Kabra Drugs Limited) has scheduled a Board of Directors meeting for September 2, 2026. The meeting will be held at the company’s corporate office in Chennai.

The primary agenda includes approving the Director’s Report and Corporate Governance Report for the financial year ended March 31, 2026. The board will also finalize logistics for the upcoming Annual General Meeting (AGM).

Key Agenda Items

The board will consider several administrative and governance matters during the session:

  • Approve the closure of the Register of Members and Share Transfer Books for AGM purposes.
  • Fix the date, time, and venue for the AGM and approve the draft notice.
  • Appoint a scrutinizer for the AGM.
  • Recommend the re-appointment of Mr. Kuniamuthur Nanjappan Anand as Director, who retires by rotation.
  • Recommend the appointment of Ms. Moonam Kapoor as Director.
  • Approve the appointment of Internal Auditors for FY27.
  • Recommend the appointment of a Secretarial Auditor for the period FY27 to FY31.

Regulatory Compliance

The intimation is issued pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has requested BSE Limited to take this information on record.

Historical Stock Returns for Kabra Drugs

1 Day5 Days1 Month6 Months1 Year5 Years
+0.76%-6.60%-17.60%-35.12%+8.49%0.0%

How might the re-appointment of Mr. Kuniamuthur Nanjappan Anand and the new appointment of Ms. Moonam Kapoor influence Aanjaay Industries' strategic direction for FY27?

What impact could the selection of the Internal Auditors for FY27 have on the company's risk management framework and operational transparency?

Given the appointment of a Secretarial Auditor for a five-year term (FY27-FY31), what long-term governance standards is Aanjaay Industries aiming to enforce?

More News on Kabra Drugs

1 Year Returns:+8.49%